The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death
Open accessAbstract
Autophagy is a cellular catabolic pathway by which long-lived proteins and damaged organelles are targeted for degradation. Activation of autophagy enhances cellular tolerance to various stresses. Recent studies indicate that a class of anticancer agents, histone deacetylase (HDAC) inhibitors, can induce autophagy. One of the HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA), is currently being used for treating cutaneous T-cell lymphoma and under clinical trials for multiple other cancer types, including glioblastoma. Here, we show that SAHA increases the expression of the autophagic factor LC3, and inhibits the nutrient-sensing kinase mammalian target of rapamycin (mTOR). The inactivation of mTOR results in the dephosphorylation, and thus activation, of the autophagic protein kinase ULK1, which is essential for autophagy activation during SAHA treatment. Furthermore, we show that the inhibition of autophagy by RNAi in glioblastoma cells results in an increase in SAHA-induced apoptosis. Importantly, when apoptosis is pharmacologically blocked, SAHA-induced nonapoptotic cell death can also be potentiated by autophagy inhibition. Overall, our findings indicate that SAHA activates autophagy via inhibiting mTOR and up-regulating LC3 expression; autophagy functions as a prosurvival mechanism to mitigate SAHA-induced apoptotic and nonapoptotic cell death, suggesting that targeting autophagy might improve the therapeutic effects of SAHA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506
Bjørkøy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Øvervatn, A., Stenmark, H., & Johansen, T. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200507002 · Cited by 3,276
Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S.-I., Natsume, T., Takehana, K., Yamada, N., et al. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1248 · Cited by 2,076
Identification of RIP1 kinase as a specific cellular target of necrostatins
Degterev, A., Hitomi, J., Germscheid, M., Ch'en, I. L., Korkina, O., Teng, X., Abbott, D., Cuny, G. D., Yuan, C., Wagner, G., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.83 · Cited by 2,059 · cited 1×
“Our preliminary studies suggest that inhibiting RIP1 kinase, a key player in death receptor-mediated necrosis by necrostatin A (27), does not inhibit cell death triggered by SAHA and zVAD cotreatment (Fig.”
BackgroundMathew, R., Karantza-Wadsworth, V., & White, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2254 · Cited by 1,798 · cited 1×
“In this context, autophagy may be regarded as a prosurvival mechanism (14).”
BackgroundTor-Mediated Induction of Autophagy via an Apg1 Protein Kinase Complex
Kamada, Y., Funakoshi, T., Shintani, T., Nagano, K., Ohsumi, M., & Ohsumi, Y. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.150.6.1507 · Cited by 1,145
Itakura, E., & Mizushima, N. (2010) · Autophagy · doi:10.4161/auto.6.6.12709 · Cited by 843 · cited 1×
“The ULK1 complex has been shown to be the most upstream component in the core autophagy pathway and is essential for autophagy induced by various conditions (18, 19).”
BackgroundVirus Inhibition of RIP3-Dependent Necrosis
Upton, J. W., Kaiser, W. J., & Mocarski, E. S. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.03.006 · Cited by 559 · cited 1×
“However, this result does not rule out necrosis, as RIP1independent necrosis has been previously reported (28).”
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450 · cited 1×
“H deacetylase (HDAC) inhibitors emerge as a new class of therapeutic agents with promising outcomes during the treatment of a wide range of cancer types (1).”
Background
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
“Several signaling pathways play a role in the induction of autophagy by HDAC inhibitors. mTOR (Mechanistic target of rapamycin) is one of the most important suppressors of autophagy via phosphorylation and inactivation of the ULK1 (Unc 51 like autophagy activating kinase 1) complex which is an upstream component of th…”
BackgroundInfluentialThe ULK1 complex: Sensing nutrient signals for autophagy activation
Wong, P.-M., Puente, C., Ganley, I. G., & Jiang, X. (2013) · Autophagy · doi:10.4161/auto.23323 · Cited by 497
Self-citationThe return of the nucleus: transcriptional and epigenetic control of autophagy
Füllgrabe, J., Klionsky, D. J., & Joseph, B. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3716 · Cited by 466
Autophagy as a molecular target for cancer treatment
Kocaturk, N. M., Akkoc, Y., Kig, C., Bayraktar, O., Gozuacik, D., & Kutlu, O. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.011 · Cited by 387
Metadata
- Authors
- Gammoh, N., Lam, D., Puente, C., Ganley, I., Marks, P. A., & Jiang, X.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-04-09
- Volume
- 109
- Issue
- 17
- Pages
- 6561-6565
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2079569618
- Cited by
- 211
- References
- 9
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.